 Evoke Pharma finally received FDA approval for Gimoti, a nasal formulation of a generic GI drug, in June 2020 and launched the drug in October 2020. Post-approval, the stock price decreased as investors dreams of the company being acquired faded, and the reality of a small company drug launch became the story. 